Regenerative Medicine and Stem Cells Technologies

Recently, Spark Therapeutics (ONCE) reported that it had achieved positive results from its phase 1/2 study using SPK-9001 to treat patients with Hemophilia B. The most notable item from this form of treatment was able to reduce routine infusions of Factor IX concentrates.

Since it burst onto the scene a decade ago, CRISPR-Cas9 has shaken the field of genetics to its core. Offering a new genomic editing tool that’s faster, cheaper and more accurate than previous approaches, it opens up an astonishing breadth of possible applications.

Private cord blood company, Smart Cells, has released their 20th sample of stem cells collected from cord blood and tissue to a patient to treat autism.

Investigators at Cedars-Sinai are exploring a new way to treat amyotrophic lateral sclerosis (ALS) by transplanting specially engineered neural cells into the brain.

The executive secretary of 3th national and international congress on the stem cell and regenerative medicine said it is essential that the Islamic Republic of Iran as the country which is moving at the borders of science and technology of the stem cells save its own excellence with holding the annual national festival in this strategic field.

UQ Faculty of Medicines Dr. Liam Coulthard said many adult diseases originated during fetal development.

The University of Texas Health Science Center at Houston (UTHealth) has received funding through a public/private partnership for the first-ever clinical trial investigating a stem cell therapy for early treatment and prevention of complications after severe traumatic injury.

An in utero stem cell transplant for a critically ill second-trimester fetus has led to the birth of an apparently healthy infant. The newborn is the first patient enrolled in the world’s first clinical trial using stem cells transplanted prior to birth.

The CRISPR-Cas9 system may be a powerful gene-editing tool, but it’s no good if the best tool in your kit can’t be applied where you want to work with it.

You need a license to cut-and-paste this copyrighted news content.